FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211680960> ?p ?o ?g. }

• W3211680960 endingPage "1314" @default.
• W3211680960 startingPage "1314" @default.
• W3211680960 abstract "Abstract Together with multicolor flow cytometry, quantitation of clonal immunoglobulin (IG) and T-cell receptor (TR) gene rearrangements represents the current standard for the detection of minimal / measurable residual disease (MRD) in treatment protocols for pediatric acute lymphoblastic leukemia (ALL) patients. Despite the adoption of next generation sequencing (NGS) in the routine identification of clonal IG/TR gene rearrangements as markers for MRD detection, real-time quantitative (q)PCR is still the standard for MRD quantitation in follow-up samples. So far, no large-scale direct comparison of qPCR- and NGS-based MRD quantitation has been performed. We compared qPCR- and NGS-MRD evaluation in a cohort of children with B-cell precursor (BCP) ALL treated on the AIEOP-BFM ALL 2009 protocol and assessed the feasibility and relevance of this method for the stratification at day 33 (EOI). In total, 459 patients were diagnosed with BCP-ALL from 2010 to 2018, and 437 of them were included in our study based on the availability of residual DNA material isolated from day 33 bone marrow aspirates and having at least one IG/TR MRD marker detectable by standard qPCR with protocol-required sensitivity of 10 -4. Sequencing libraries were prepared according to the EuroClonality-NGS group SOP (Brüggemann et al, Leukemia 2019) with the total DNA input normalized to the equivalent of 150,000 nucleated cells to reach MRD sensitivity of 10 -5 and sequenced on Illumina NovaSeq and MiSeq instruments. In total of 780 IG/TR markers evaluated by both NGS and qPCR. Sequencing data were analyzed using the ARResT/Interrogate (Bystry et at, Bioinformatics 2017) pipeline and a custom bioinformatic analysis process and the NGS-MRD results were normalized to the EuroClonality-NGS central in-tube quality/quantification control (cIT-QC; Knecht et al, Leukemia 2019). From the total 780 IG/TR MRD markers evaluated by both methods, 629 (80.6%) were concordant with 242 markers being MRD positive and 387 negative. From 82 markers that were only positive by qPCR and not by NGS, 76 were positive below the quantitative range (positive non-quantifiable). Specificity analysis was performed for each marker by searching for the junction sequence across the dataset of all patients' NGS results. Based on these results, 22 out of 82 markers positive only by qPCR were classified as potentially unspecific (false positive) and similarly 32 unspecific markers were identified among the 69 positive only by NGS. This was also supported by unspecific amplification of the polyclonal control in 27 out of these 32 corresponding qPCR systems, in some cases leading to qPCR negative classification determined by the EuroMRD guidelines. Overall stratification of patients based only on day 33 MRD by qPCR or NGS was concordant in 76% of patients by both methods, while in 19% of patients, NGS-MRD quantitation led to the assignment to a lower-risk group, mainly due to the elimination of false-positive results. Furthermore, analysis of all positive markers across all patients' NGS libraries showed, that one out of 10 markers (mainly in the IGK, TRG and TRD loci) used for qPCR-MRD stratification did not provide satisfactory specificity, although they fully met EuroMRD criteria during the optimization of qPCR patient-specific assays. Our results show that NGS-MRD is highly concordant with traditional qPCR-based strategy and has comparable sensitivity and clinical value in the setting of a BFM-based clinical protocol, while being less laborious and providing significantly more specific results and additional information on the IG/TR repertoire (Kotrova et al, Blood 2016). Our study also emphasizes the importance of selecting MRD markers of adequate specificity at diagnosis. Currently, this selection can be assisted by these broad sequencing data on IG/TR repertoire of large number of patients. Based on these results, we propose that frontline NGS-MRD evaluation developed by the EuroClonality-NGS working group can be used as an alternative to traditional qPCR-based MRD quantitation in future MRD-based treatment protocols. Supported by grants NU20-03-00284 and NU20-07-00322 from the Czech Health Research Council and 534120 from Charles University. All methods were established through collaboration within the EuroClonality-NGS and EuroMRD groups. Disclosures van der Velden: Agilent: Research Funding; Navigate: Other: Service Level Agreement; Janssen: Other: Service Level Agreement; EuroFlow: Other: Service Level Agreement, Patents & Royalties: for network, not personally; BD Biosciences: Other: Service Level Agreement. Brüggemann: Incyte: Other: Advisory Board; Janssen: Speakers Bureau; Amgen: Other: Advisory Board, Travel support, Research Funding, Speakers Bureau. Langerak: Erasmus MS, University Medical Center: Current Employment; F. Hoffmann-La Roche Ltd/Genentech, Inc.: Research Funding; Gilead: Research Funding; Janssen: Speakers Bureau." @default.
• W3211680960 created "2021-11-22" @default.
• W3211680960 creator A5025706257 @default.
• W3211680960 creator A5027341200 @default.
• W3211680960 creator A5028110023 @default.
• W3211680960 creator A5034740632 @default.
• W3211680960 creator A5045095325 @default.
• W3211680960 creator A5045344479 @default.
• W3211680960 creator A5052715071 @default.
• W3211680960 creator A5052733565 @default.
• W3211680960 creator A5056374762 @default.
• W3211680960 creator A5065448452 @default.
• W3211680960 creator A5074556461 @default.
• W3211680960 creator A5075073484 @default.
• W3211680960 creator A5076709979 @default.
• W3211680960 creator A5086305480 @default.
• W3211680960 date "2021-11-05" @default.
• W3211680960 modified "2023-10-16" @default.
• W3211680960 title "NGS-Based MRD Quantitation: An Alternative to qPCR Validated on a Large Consecutive Cohort of Children with ALL" @default.
• W3211680960 doi "https://doi.org/10.1182/blood-2021-152971" @default.
• W3211680960 hasPublicationYear "2021" @default.
• W3211680960 type Work @default.
• W3211680960 sameAs 3211680960 @default.
• W3211680960 citedByCount "2" @default.
• W3211680960 countsByYear W32116809602023 @default.
• W3211680960 crossrefType "journal-article" @default.
• W3211680960 hasAuthorship W3211680960A5025706257 @default.
• W3211680960 hasAuthorship W3211680960A5027341200 @default.
• W3211680960 hasAuthorship W3211680960A5028110023 @default.
• W3211680960 hasAuthorship W3211680960A5034740632 @default.
• W3211680960 hasAuthorship W3211680960A5045095325 @default.
• W3211680960 hasAuthorship W3211680960A5045344479 @default.
• W3211680960 hasAuthorship W3211680960A5052715071 @default.
• W3211680960 hasAuthorship W3211680960A5052733565 @default.
• W3211680960 hasAuthorship W3211680960A5056374762 @default.
• W3211680960 hasAuthorship W3211680960A5065448452 @default.
• W3211680960 hasAuthorship W3211680960A5074556461 @default.
• W3211680960 hasAuthorship W3211680960A5075073484 @default.
• W3211680960 hasAuthorship W3211680960A5076709979 @default.
• W3211680960 hasAuthorship W3211680960A5086305480 @default.
• W3211680960 hasConcept C104317684 @default.
• W3211680960 hasConcept C126322002 @default.
• W3211680960 hasConcept C143998085 @default.
• W3211680960 hasConcept C203014093 @default.
• W3211680960 hasConcept C2778461978 @default.
• W3211680960 hasConcept C2779823535 @default.
• W3211680960 hasConcept C49105822 @default.
• W3211680960 hasConcept C51679486 @default.
• W3211680960 hasConcept C54355233 @default.
• W3211680960 hasConcept C71924100 @default.
• W3211680960 hasConcept C86803240 @default.
• W3211680960 hasConceptScore W3211680960C104317684 @default.
• W3211680960 hasConceptScore W3211680960C126322002 @default.
• W3211680960 hasConceptScore W3211680960C143998085 @default.
• W3211680960 hasConceptScore W3211680960C203014093 @default.
• W3211680960 hasConceptScore W3211680960C2778461978 @default.
• W3211680960 hasConceptScore W3211680960C2779823535 @default.
• W3211680960 hasConceptScore W3211680960C49105822 @default.
• W3211680960 hasConceptScore W3211680960C51679486 @default.
• W3211680960 hasConceptScore W3211680960C54355233 @default.
• W3211680960 hasConceptScore W3211680960C71924100 @default.
• W3211680960 hasConceptScore W3211680960C86803240 @default.
• W3211680960 hasIssue "Supplement 1" @default.
• W3211680960 hasLocation W32116809601 @default.
• W3211680960 hasOpenAccess W3211680960 @default.
• W3211680960 hasPrimaryLocation W32116809601 @default.
• W3211680960 hasRelatedWork W1969475579 @default.
• W3211680960 hasRelatedWork W2014506455 @default.
• W3211680960 hasRelatedWork W2028845178 @default.
• W3211680960 hasRelatedWork W2099866477 @default.
• W3211680960 hasRelatedWork W2106899282 @default.
• W3211680960 hasRelatedWork W2409906287 @default.
• W3211680960 hasRelatedWork W2411814702 @default.
• W3211680960 hasRelatedWork W2435859457 @default.
• W3211680960 hasRelatedWork W2525403055 @default.
• W3211680960 hasRelatedWork W2588137614 @default.
• W3211680960 hasVolume "138" @default.
• W3211680960 isParatext "false" @default.
• W3211680960 isRetracted "false" @default.
• W3211680960 magId "3211680960" @default.
• W3211680960 workType "article" @default.